Bladder Cancer Immunotherapy: BCG and Beyond

被引：101

作者：

Askeland, Eric J. ^{[1
]}

Newton, Mark R. ^{[1
]}

O'Donnell, Michael A. ^{[1
]}

Luo, Yi ^{[1
]}

机构：

[1] Univ Iowa, Dept Urol, 375 Newton Rd,3204 MERF, Iowa City, IA 52242 USA

来源：

ADVANCES IN UROLOGY | 2012年 / 2012卷

关键词：

D O I：

10.1155/2012/181987

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 [临床医学]; 100201 [内科学];

摘要：

Mycobacterium bovis bacillus Calmette-Guerin (BCG) has become the predominant conservative treatment for nonmuscle invasive bladder cancer. Its mechanism of action continues to be defined but has been shown to involve a T helper type 1 (Th1) immunomodulatory response. While BCG treatment is the current standard of care, a significant proportion of patients fails or do not tolerate treatment. Therefore, many efforts have been made to identify other intravesical and immunomodulating therapeutics to use alone or in conjunction with BCG. This paper reviews the progress of basic science and clinical experience with several immunotherapeutic agents including IFN-alpha, IL-2, IL-12, and IL-10.

引用

页数：13

共 164 条

[1]

Intratumoral coinjection of adenoviral vectors expressing IL-2 and IL-12 results in enhanced frequency of regression of injected and untreated distal tumors [J].

Addison, CL ;

Bramson, JL ;

Hitt, MM ;

Muller, WJ ;

Gauldie, J ;

Graham, FL .

GENE THERAPY, 1998, 5 (10) :1400-1409

[2]

Atkins MB, 1997, CLIN CANCER RES, V3, P409

[3]

DETECTION OF URINARY INTERLEUKIN-2, INTERLEUKIN-2 RECEPTOR, AND TUMOR-NECROSIS-FACTOR LEVELS IN PATIENTS WITH SUPERFICIAL BLADDER-TUMORS AFTER INTRAVESICAL BCG IMMUNOTHERAPY [J].

BALBAY, D ;

BAKKALOGLU, M ;

OZEN, H ;

TASAR, C ;

OZKARDES, H ;

REMZI, D ;

BARUT, A .

UROLOGY, 1994, 43 (02) :187-190

[4]

Co-administration of intravesical bacillus Calmette-Guerin and interferon α-2B as first line in treating superficial transitional cell carcinoma of the urinary bladder [J].

Bazarbashi, Shouki ;

Soudy, Hussein ;

Abdelsalam, Mahmoud ;

Al-Jubran, Ali ;

Akhtar, Saad ;

Memon, Muhammad ;

Aslam, Muhammad ;

Kattan, Said ;

Shoukri, Mohamed .

BJU INTERNATIONAL, 2011, 108 (07) :1115-1118

[5]

Interferon-alpha in tumor immunity and immunotherapy [J].

Belardelli, F ;

Ferrantini, M ;

Proietti, E ;

Kirkwood, JM .

CYTOKINE & GROWTH FACTOR REVIEWS, 2002, 13 (02) :119-134

[6]

Anti-Interleukin-10R1 Monoclonal Antibody Enhances Bacillus Calmette-Guerin Induced T-Helper Type 1 Immune Responses and Antitumor Immunity in a Mouse Orthotopic Model of Bladder Cancer [J].

Bockholt, Nathan A. ;

Knudson, Matthew J. ;

Henning, Jonathan R. ;

Maymi, Jose L. ;

Weady, Peter ;

Smith, George J., III ;

Eisenbraun, Michael D. ;

Fraser, James D. ;

O'Donnell, Michael A. ;

Luo, Yi .

JOURNAL OF UROLOGY, 2012, 187 (06) :2228-2235

[7]

Bohle A, 1990, Cytokine, V2, P175, DOI 10.1016/1043-4666(90)90013-J

[8]

Direct intratumoral injection of an adenovirus expressing interleukin-12 induces regression and long-lasting immunity that is associated with highly localized expression of interleukin-12 [J].

Bramson, JL ;

Hitt, M ;

Addison, CL ;

Muller, WJ ;

Gauldie, J ;

Graham, FL .

HUMAN GENE THERAPY, 1996, 7 (16) :1995-2002

[9]

ANTITUMOR AND ANTIMETASTATIC ACTIVITY OF INTERLEUKIN-12 AGAINST MURINE TUMORS [J].

BRUNDA, MJ ;

LUISTRO, L ;

WARRIER, RR ;

WRIGHT, RB ;

HUBBARD, BR ;

MURPHY, M ;

WOLF, SF ;

GATELY, MK .

JOURNAL OF EXPERIMENTAL MEDICINE, 1993, 178 (04) :1223-1230

[10]

INTERLEUKIN-4 AND INTERLEUKIN-10 INHIBIT NITRIC OXIDE-DEPENDENT MACROPHAGE KILLING OF CANDIDA-ALBICANS [J].

CENCI, E ;

ROMANI, L ;

MENCACCI, A ;

SPACCAPELO, R ;

SCHIAFFELLA, E ;

PUCCETTI, P ;

BISTONI, F .

EUROPEAN JOURNAL OF IMMUNOLOGY, 1993, 23 (05) :1034-1038

← 1 2 3 4 5 6 7 8 9 10 →